Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line

BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics (“RevOpsis”), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies. This agreement follows a successful cell line development campaign with Asimov’s CHO Edge System for the lead RevOpsis asset, RO-104. Unde